Edition:
United States

Motif Bio PLC (MTFB.OQ)

MTFB.OQ on NASDAQ Stock Exchange Capital Market

8.89USD
17 Aug 2018
Change (% chg)

$0.08 (+0.91%)
Prev Close
$8.81
Open
$8.89
Day's High
$8.89
Day's Low
$8.89
Volume
100
Avg. Vol
789
52-wk High
$13.70
52-wk Low
$6.97

Latest Key Developments (Source: Significant Developments)

Motif Bio Announces FDA Acceptance Of New Drug Application With Priority Review For Iclaprim
Tuesday, 14 Aug 2018 02:00am EDT 

Aug 14 (Reuters) - Motif Bio PLC ::MOTIF BIO ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR ICLAPRIM FOR TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS.  Full Article

Motif Bio Says 2017 Net Loss Widened To $44.8 Mln
Tuesday, 10 Apr 2018 02:01am EDT 

April 10 (Reuters) - Motif Bio PLC ::REPORTED A NET LOSS OF $44.8 MILLION FOR 2017 COMPARED TO A NET LOSS OF $40.3 MILLION IN 2016.GROSS CASH AND CASH EQUIVALENTS WERE $22.7 MILLION AS OF DECEMBER 31, 2017.DEBT FINANCING OF $20 MILLION SUCCESSFULLY COMPLETED; $15 MILLION HAS BEEN DRAWN DOWN.  Full Article

Motif Bio Announces Update On NDA Submission For Iclaprim
Tuesday, 20 Mar 2018 03:00am EDT 

March 20 (Reuters) - Motif Bio Plc ::MOTIF BIO UPDATE ON NDA SUBMISSION FOR ICLAPRIM.‍CO HAS DECIDED THAT IN ORDER TO ENSURE A COMPLETE AND HIGH QUALITY SUBMISSION, IT WOULD BE PRUDENT TO TAKE ADDITIONAL TIME​.‍NOW EXPECTS THAT NDA WILL BE SUBMITTED TO FDA DURING Q2 OF 2018​.  Full Article

Motif Bio Says ‍Robert Dickey To Resign As CFO
Friday, 2 Feb 2018 10:00am EST 

Feb 2 (Reuters) - Motif Bio Plc ::MOTIF BIO PLC - ‍ROBERT DICKEY IV HAS INFORMED COMPANY OF HIS INTENTION TO RESIGN FROM HIS ROLE AS CHIEF FINANCIAL OFFICER​.MOTIF BIO PLC - SEARCH PROCESS FOR NEW CFO HAS COMMENCED; JONATHAN GOLD, CURRENTLY NON-EXECUTIVE DIRECTOR OF CO, HAS AGREED TO SERVE AS INTERIM CFO.  Full Article

Motif Bio Plc To Offer And Sell Up To 1.2 Mln ADR
Wednesday, 13 Dec 2017 05:12pm EST 

Dec 13 (Reuters) - Motif Bio Plc ::MOTIF BIO PLC FILES FOR OFFER AND SALE OF UP TO 1.2 MILLION AMERICAN DEPOSITARY SHARES - SEC FILING.  Full Article

Motif Bio secures up to US$20 million debt financing
Wednesday, 15 Nov 2017 02:00am EST 

Nov 15 (Reuters) - Motif Bio Plc -:Motif Bio secures up to US$20 million debt financing.‍Company has entered into an agreement for up to US$20 million in debt financing with Hercules Capital, Inc​.‍Co shall issue Hercules warrants to purchase up to 73,452 of its American Depository Shares at exercise price of US$9.53 per ADS.  Full Article

Motif Bio ‍announces positive topline results for iclaprim in revive-2 phase 3 study​
Wednesday, 4 Oct 2017 02:00am EDT 

Oct 4 (Reuters) - Motif Bio Plc :POSITIVE TOPLINE RESULTS IN PHASE THREE STUDY.‍ANNOUNCES POSITIVE TOPLINE RESULTS FOR ICLAPRIM IN REVIVE-2 PHASE 3 STUDY​.‍ICLAPRIM WAS WELL TOLERATED IN STUDY​.‍NDA SUBMISSION EXPECTED IN Q1 OF 2018​.  Full Article

Motif Bio says iclaprim granted orphan drug designation by US FDA
Friday, 15 Sep 2017 09:07am EDT 

Sept 15 (Reuters) - MOTIF BIO PLC ::SAYS US FDA HAS GRANTED ITS INVESTIGATIONAL DRUG CANDIDATE, ICLAPRIM, ORPHAN DRUG DESIGNATION FOR TREATMENT OF STAPHYLOCOCCUS AUREUS LUNG INFECTIONS IN PATIENTS WITH CYSTIC FIBROSIS.  Full Article

Motif Bio says announces pricing of $25 mln U.S. IPO and European placing
Friday, 18 Nov 2016 08:47am EST 

Motif Bio Plc : Says each ADS, representing 20 ordinary shares of Motif, warrant to purchase 0.5 ADSs offered at price of $6.98/ADS and warrant combination .Says announces pricing of $25 million U.S. Initial public offering and European placing.  Full Article

Motif Bio sees IPO of 42.5 million ordinary shares
Thursday, 13 Oct 2016 06:03am EDT 

Motif Bio Plc : Motif Bio Plc sees IPO of 42.5 million ordinary shares including in form of American depositary shares - SEC filing .Motif Bio intends to use about $20.5 million of IPO proceeds to fund expenses to be incurred in conducting two Phase 3 clinical trials of Iclaprim.  Full Article

BRIEF-Motif Bio Says 2017 Net Loss Widened To $44.8 Mln

* REPORTED A NET LOSS OF $44.8 MILLION FOR 2017 COMPARED TO A NET LOSS OF $40.3 MILLION IN 2016